HUMANA INC
Business
Humana Inc. is a health insurance and healthcare services company offering managed care plans including Medicare Advantage, Medicaid, and prescription drug plans. The company integrates insurance with healthcare delivery through owned pharmacy, primary care, and home health operations serving health plan members and third parties. Humana operates two reportable segments: Insurance, which includes health plans and pharmacy benefit management, and CenterWell, which provides pharmacy, primary care, and home health services. The company derives substantial revenue from federal government contracts.
Summary from 10-K filed 2026-02-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Premiums | 122,825 | 112,104 | 101,272 | 87,712 | 79,822 | |
| Services | 5,833 | 4,431 | 4,033 | 4,776 | 3,055 | |
| Investment income | 1,006 | 1,226 | 1,069 | 382 | 187 | |
| Total revenues | 129,664 | 117,761 | 106,374 | 92,870 | 83,064 | |
| Benefits | 110,812 | 100,664 | 88,394 | 75,690 | — | |
| Operating costs | 15,450 | 13,696 | 13,188 | 12,671 | 10,121 | |
| Depreciation and amortization | 698 | 839 | 779 | 709 | 596 | |
| Total operating expenses | 126,960 | 115,199 | 102,361 | 89,070 | 79,916 | |
| Income (loss) from operations | 2,704 | 2,562 | 4,013 | 3,800 | 3,148 | |
| Loss on sale of business | 67 | 0 | 0 | −237 | 0 | |
| Interest expense | 631 | 660 | 493 | 401 | — | |
| Other expense, net | 451 | 181 | 137 | 68 | −532 | |
| Income before income taxes and equity in net losses | 1,555 | 1,721 | 3,383 | 3,568 | 3,354 | |
| Provision for income taxes | 250 | 413 | 836 | 762 | 485 | |
| Equity in net losses | −102 | −94 | −63 | −4 | 65 | |
| Net income | 1,203 | 1,214 | 2,484 | 2,802 | 2,934 | |
| Net (income) loss attributable to noncontrolling interests | −15 | −7 | 5 | 4 | −1 | |
| Net income attributable to Humana | 1,188 | 1,207 | 2,489 | 2,806 | 2,933 | |
| Basic earnings per common share (in dollars per share) | 9.87 | 10.01 | 20.09 | 22.2 | 22.79 | |
| Diluted earnings per common share (in dollars per share) | 9.84 | 9.98 | 20 | 22.08 | 22.67 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4,200 | 2,221 | 4,694 | 5,061 | 3,394 | |
| Investment securities | 15,703 | 18,214 | 16,626 | 13,881 | 13,192 | |
| Receivables, net of allowances of $108 in 2025 and $98 in 2024 | 3,270 | 2,704 | 2,035 | 1,674 | 1,814 | |
| Other current assets | 9,560 | 6,676 | 6,631 | 5,567 | 6,493 | |
| Total current assets | 32,733 | 29,815 | 29,986 | 26,183 | 24,893 | |
| Property and equipment, net | 2,231 | 2,532 | 3,030 | 3,221 | 3,073 | |
| Long-term investment securities | 493 | 421 | 382 | 380 | 780 | |
| Goodwill | 9,686 | 9,631 | 9,550 | 9,142 | 11,092 | |
| Equity method investments | 638 | 697 | 740 | 749 | 141 | |
| Other long-term assets | 3,128 | 3,383 | 3,377 | 3,380 | 4,379 | |
| Total assets | 48,909 | 46,479 | 47,065 | 43,055 | 44,358 | |
| Benefits payable | 9,967 | 10,440 | 10,241 | 9,264 | 8,289 | |
| Trade accounts payable and accrued expenses | 5,717 | 5,259 | 6,569 | 5,238 | 4,509 | |
| Book overdraft | 306 | 403 | 353 | 298 | 326 | |
| Unearned revenues | 356 | 260 | 266 | 286 | 254 | |
| Short-term debt | 0 | 577 | 1,443 | 2,092 | 1,953 | |
| Total current liabilities | 16,346 | 16,939 | 18,872 | 17,178 | 15,331 | |
| Long-term debt | 12,369 | 11,144 | 10,213 | 9,034 | 10,541 | |
| Other long-term liabilities | 2,457 | 1,951 | 1,662 | 1,473 | 2,383 | |
| Total liabilities | 31,172 | 30,034 | 30,747 | 27,685 | 28,255 | |
| Commitments and contingencies (Note 17) | — | — | — | — | — | |
| Preferred stock, $1 par; 10,000,000 shares authorized; none issued | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,719,321 shares issued at December 31, 2025 and 198,718,810 shares issued at December 31, 2024 | 33 | 33 | 33 | 33 | 33 | |
| Capital in excess of par value | 3,600 | 3,463 | 3,346 | 3,246 | 3,082 | |
| Retained earnings | 29,075 | 28,317 | 27,540 | 25,492 | 23,086 | |
| Accumulated other comprehensive loss | −633 | −1,067 | −999 | −1,304 | 42 | |
| Treasury stock, at cost, 78,128,009 shares at December 31, 2025 and 78,077,195 shares at December 31, 2024 | −14,418 | −14,371 | −13,658 | −12,156 | −10,163 | |
| Total stockholders' equity | 17,657 | 16,375 | 16,262 | 15,311 | 16,080 | |
| Noncontrolling interests | 80 | 70 | 56 | 59 | 23 | |
| Total equity | 17,737 | 16,445 | 16,318 | 15,370 | 16,103 | |
| Total liabilities and equity | 48,909 | 46,479 | 47,065 | 43,055 | 44,358 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Loss (gain) on investment securities, net | 50 | −24 | 54 | 205 | 130 | |
| Stock-based compensation | 241 | 207 | 175 | 216 | 180 | |
| Depreciation | 773 | 908 | 850 | 749 | 640 | |
| Amortization | 51 | 60 | 67 | 96 | 73 | |
| Impairment of property and equipment | 28 | 237 | 206 | 248 | 0 | |
| Impairment of indefinite-lived intangible assets | 128 | 200 | 55 | 0 | 0 | |
| Deferred income taxes | 75 | −192 | −167 | −100 | 15 | |
| Receivables | −570 | −669 | −337 | −54 | −280 | |
| Other assets | −2,173 | 1,003 | −1,318 | −463 | −491 | |
| Benefits payable | −472 | 199 | 915 | 975 | 104 | |
| Other liabilities | 1,322 | −373 | 841 | 44 | 176 | |
| Unearned revenues | 96 | −6 | −20 | 32 | −65 | |
| Other, net | 0 | 108 | 113 | 70 | 40 | |
| Net cash provided by operating activities | 921 | 2,966 | 3,981 | 4,587 | 2,262 | |
| Proceeds from sale of business, net | 115 | 0 | 0 | 2,701 | 0 | |
| Acquisitions, net of cash and cash equivalents acquired | −81 | −89 | −233 | −337 | −4,187 | |
| Purchases of property and equipment | −546 | −575 | −1,004 | −1,137 | −1,342 | |
| Proceeds from sale of property and equipment | 23 | 7 | 210 | 17 | 26 | |
| Changes in securities lending collateral receivable | −220 | −418 | 0 | 0 | — | |
| Purchases of investment securities | −6,440 | −8,185 | −7,552 | −6,049 | −7,197 | |
| Proceeds from maturities of investment securities | 2,912 | 2,982 | 1,292 | 1,365 | 2,597 | |
| Proceeds from sales of investment securities | 6,510 | 3,376 | 3,795 | 2,434 | 3,547 | |
| Other | 0 | −50 | 0 | 0 | — | |
| Net cash provided by (used in) investing activities | 2,273 | −2,952 | −3,492 | −1,006 | −6,556 | |
| (Payments) receipts from contract deposits, net | −1,076 | −1,933 | 828 | 1,993 | −306 | |
| Proceeds from issuance of senior notes, net | 1,481 | 2,232 | 2,544 | 1,982 | 2,984 | |
| Repayment of senior notes | −948 | −1,107 | −1,832 | −1,000 | 0 | |
| (Repayments) proceeds from issuance of commercial paper, net | −5 | −907 | 211 | −376 | 352 | |
| Proceeds from short-term borrowings | 0 | 0 | 100 | 0 | 0 | |
| Repayment of short-term borrowings | 0 | 0 | −100 | 0 | 0 | |
| Repayment of term loan | 0 | 0 | −500 | −2,000 | −2,078 | |
| Debt issue costs | −5 | −7 | −7 | −6 | −31 | |
| Common stock repurchases | −151 | −817 | −1,573 | −2,096 | −79 | |
| Dividends paid | −430 | −431 | −431 | −392 | −354 | |
| Changes in securities lending payable | 220 | 418 | 0 | 0 | — | |
| Changes in rebate factor payable | −123 | 123 | 0 | 0 | — | |
| Change in book overdraft | −97 | 50 | 55 | −28 | 6 | |
| Other, net | −81 | −108 | −151 | 9 | 21 | |
| Net cash used in financing activities | −1,215 | −2,487 | −856 | −1,914 | 3,015 | |
| Increase (decrease) in cash and cash equivalents | 1,979 | −2,473 | −367 | 1,667 | −1,279 | |
| Interest payments | 628 | 584 | 394 | 354 | 285 | |
| Fair value of assets acquired, net of cash acquired | 91 | 124 | 462 | 460 | 9,804 | |
| Less: Fair value of liabilities assumed | −10 | −35 | −234 | −70 | −3,235 | |
| Less: Noncontrolling interests acquired | 0 | 0 | 5 | −53 | −22 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is HUMANA INC's CIK number?
HUMANA INC's SEC CIK number is 0000049071 (49071). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find HUMANA INC's SEC filings?
All of HUMANA INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did HUMANA INC last report earnings?
HUMANA INC (HUM) most recently filed an earnings 8-K with the SEC on Apr 29, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000049071-26-000021). This is HUMANA INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is HUMANA INC's most recent earnings 8-K?
HUMANA INC's latest earnings 8-K (Item 2.02) was filed Apr 29, 2026 under accession 0000049071-26-000021. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View HUMANA INC's latest earnings 8-K →
Look up any company's CIK number →